According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to treat ... various strengths are being recalled by Glenmark Pharmaceuticals ...

Unlike stimulant-based drugs that make up the bulk of ADHD treatment, including those like Vyvanse and Adderall, atomoxetine is a selective norepinephrine reuptake inhibitor (sNRI). The recall was ...

Opens in a new tab or window Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine due to the presence of a possible carcinogen.

The company is recalling the affected lot due to “CGMP Deviations”, the US Food and Drug Administration (USFDA) said in its latest Enforcement Report. The recall ... is remote. ADHD is a ...

Glenmark Pharma recalls 114 batches of hypokalemia drug in U.S. The recall is due to ... of serious adverse health consequences is remote. ADHD is a neurodevelopmental disorder that affects ...

Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine due to the presence of a possible carcinogen. (Fierce Pharma ...

The companies in question, Dr. Reddy’s Laboratories, Sun Pharma and Zydus Pharmaceuticals, are recalling seizure treatments, ...

Glenmark Pharmaceuticals, an India-based drug manufacturer has issued a voluntary recall affecting nearly 1.48 million bottles of atomoxetine, a generic medication used to treat ADHD. The recall ...

Developed by the World Health Organisation and experts from Harvard Medical School, the screening tool is comprised of 18 ...

In fact, Sibley, at the University of Washington, recalls how early on ... at our office telling us they have ADHD,” Antshel ...

We are doing our best to maintain sunny spirits, though, because once again, we recall some helpful wisdom ... The U.S. Food and Drug Administration wants bulk production of copycat versions ...